Illumina, Inc. (ILMN) Stock Price & How to Invest

Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers. Its business follows a razor-and-blades model: instruments such as the high-throughput NovaSeq X, the NextSeq, and the benchtop MiSeq seed an installed base, and the bulk of revenue then comes from recurring sequencing consumables (reagents and flow cells), which historically make up the majority of sales. The company is also pushing into multiomics, proteomics, and clinical diagnostics to expand what its platforms can measure. Illumina is headquartered in San Diego, was founded in 1998, and is led by CEO Jacob Thaysen.

Illumina's recent history was dominated by its acquisition of cancer-screening company GRAIL and the regulatory fight that followed. Antitrust authorities in the US and Europe challenged the deal, the European Commission ordered a divestiture in 2023, and Illumina distributed about 85.5% of GRAIL to its shareholders in June 2024, separating the two companies. In September 2024 the European Court of Justice annulled the Commission's jurisdiction over the original review, and Illumina avoided a 432 million euro fine. With GRAIL gone, management has refocused the company on its core sequencing platforms, consumables growth, multiomics, and operating-margin recovery.

Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. The underlying sequencing market is growing slowly, and soft academic and research funding, including pressure on US research budgets, can delay instrument purchases. China is now only about 3% of revenue after Illumina was effectively shut out of that market, where domestic players BGI and MGI dominate. Tariffs and a relatively high valuation add further risk.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Illumina, Inc.'s investor relations page or your broker.

• Revenue (FY2025): ~$4.34 billion (approximate, verify)
• 2026 revenue guidance: ~$4.5-4.6 billion, ~4-6% growth (company guidance, verify)
• Consumables mix: Majority of revenue is recurring consumables (razor-and-blades; verify)
• Non-GAAP operating margin (2026 guide): ~23.3-23.5% (company guidance, verify)
• P/E (TTM): ~32x (approximate, moves with price; verify)
• Market cap: ~$26-27 billion (approximate, verify)

Illumina trades at a premium earnings multiple that reflects its platform dominance and consumables annuity, set against low-single-digit revenue growth and a slow-growing end market. Full-year 2025 revenue was about $4.34 billion, and the company guided fiscal 2026 to roughly $4.5 to $4.6 billion with operating margins recovering toward the low-to-mid 20s. All figures are approximate, tied to the June 2026 asOf date, and move with the share price and reported results; verify current numbers before relying on them.

There are three common ways to get ILMN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ILMN sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where ILMN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Illumina (ILMN) today is a focused sequencing company whose main driver is the consumables pulled through its growing NovaSeq X installed base, which reached roughly 890 instruments by the end of 2025, against full-year 2025 revenue of about $4.34 billion. If you believe Illumina keeps its platform lead and consumables annuity intact while operating margins recover, the question becomes sizing and overlap with other healthcare or genomics positions you hold, not timing. The risk is that competition from lower-cost sequencers, soft research funding, and lost China sales keep top-line growth in the low-single digits.

Whether ILMN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ILMN a buy?, and where the stock could go from here in the ILMN stock forecast.

For income investors, whether ILMN pays a dividend and how the payout looks is covered in does ILMN pay a dividend?